Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
CAMBRIDGE, Mass. and BERLIN /PRNewswire-FirstCall/ -- Genzyme
Corporation and Bayer Schering Pharma AG, Germany announce that important,
new clinical data will be presented this weekend from two studies regarding
alemtuzumab use in patients with multiple sclerosis (MS) at the 23rd
Congress of ...
Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018
...s. The report also finds that three additional emerging agents - Biogen Idec's pegylated interferon-beta-1a, Genzyme/Bayer Schering/Bayer HealthCare's alemtuzumab
(currently marketed as Campath/MabCampath) and BioMS Medical/Eli Lilly's dirucotide - will also contribute substantially to market growth by providing...
GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
...wed limited or no response to both fludarabine and alemtuzumab
treatment (fludarabine alemtuzumab
refractory) and patients who were refractory to fl...rabine and considered inappropriate candidates for alemtuzumab
due to bulky tumor masses (>5 cm) in their lymp...
Researchers find predictive tests and early treatment delay progression of blood cell cancer
...rimental treatments if appropriate.
The two targeted therapies studied, alemtuzumab
and rituximab, are widely used in advanced-stage CLL. Both are monoclonal a...treatment with chemotherapy and monoclonal antibodies such as rituximab and alemtuzumab
can be prescribed, but these treatments do not cure the disease.
Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients
... Donaldson J, Basu A, et al. 411 Living donor kidney transplants using alemtuzumab
pre-conditioning and tacrolimus monotherapy: 5 year experience. Abstra...Rejection characteristics of 200 living donor kidney transplants using alemtuzumab
induction and tacrolimus monotherapy: 3 year follow-up. Abstract no. 2...
Multiple Independent Studies Report on Use of Cylex's Immune Cell Function Assay in Postoperative Monitoring of Kidney, Liver, and Heart Transplant Recipients
-- "411 living donor kidney transplants using alemtuzumab
pre-conditioning and tacrolismus monotherapy: ... date) of living kidney donor transplants with alemtuzumab
preconditioning, including the role of the Cyl... of 200 living donor kidney transplants using alemtuzumab
induction and tacrolismus monotherapy" (H. P. Tan,...
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
...erixafor) for stem-cell transplantation and alemtuzumab
for multiple sclerosis.
Fourth-Quarter 2007 High... clinical trials-particularly the phase 3 study of alemtuzumab
for multiple sclerosis; and (3) product launch...l pipeline. The product will join Mozobil and alemtuzumab
at the forefront of a development portfolio with ...
Alemtuzumab in Medical Technology
Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy
The results of these studies will be presented during the American Transplant Congress in Boston , MA May 30 - June 3, 2009
COLUMBIA, Md., May 31 /PRNewswire/ -- The results of two large studies presented by researchers from the Starzl Transplant Institute at the University of P...
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Three-Year Analysis Demonstrates Robust, Highly Statistically Significant Treatment Effect of Alemtuzumab
Compared to Rebif(R)
CAMBRIDGE, Mass., Oct. 15 /PRNewswire-FirstCall/ -- Genzyme Corporation
(Nasdaq: GENZ ) today announced that top-line, three-year data from a
completed Phase ...
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
CAMBRIDGE, Mass., and BERLIN, Sept. 26 /PRNewswire-FirstCall/ --
Genzyme Corporation (Nasdaq: GENZ ) and Bayer Schering Pharma AG, Germany
today announced that the first patient has been treated in the first of two
planned Phase 3 trials examining the safety and efficacy of alemtuzumab
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
...ed a combination of cyclophosphamide, fludarabine, alemtuzumab
(Campath) and rituximab (CFAR) as a frontline ther...e of B-Cell Chronic Lymphocytic Leukemia Following alemtuzumab
Therapy: Retrospective Study within Various Cytoge...points.
(Campath) in Fludarabine-Refractory CLL: Final Res...
Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
...r no response (refractory) to both fludarabine and alemtuzumab
treatment (double refractory; DR), and patients wh...rabine and considered inappropriate candidates for alemtuzumab
due to bulky tumor masses in their lymph nodes (bu...nts whose disease is refractory to fludarabine and alemtuzumab
treatment or patients who are refractory to fludar...
Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
.... PST) -- Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following alemtuzumab
Therapy: Retrospective Study Within Various Cytogenetic Risk Categories
Poster 329 (December 8, 12:00 p.m. PST) -- Subcutaneous alemtuzumab
(Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial o...
Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
...rabine and considered inappropriate candidates
due to bulky tumor in their lymph nodes. An object...ne and
alemtuzumab. In the fludarabine refractory, alemtuzumab
patient group, an objective response...atients who are refractory to
both fludarabine and alemtuzumab
and patients who are refractory to
Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients
...nalysis, while also being prospectively monitored and
classified for episodes of infection according to standardized criteria.
All patients received alemtuzumab
induction and tacrolimus suppression
to prevent organ rejection. Results of ImmuKnow assays of CMI were included
in the analysis if and when they were...
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year
Alemtuzumab in Multiple Sclerosis Data Presented at AAN
...ative study showed significant
results in favor of alemtuzumab
CAMBRIDGE, Mass. and WAYNE, N.J., Ma...
Dr. Coles' presentation showed patients taking alemtuzumab
the high dose experienced an 87 percent reducti...eated with Rebif. At the low dose, patients
experienced similar results, with a 72 percent
Alemtuzumab in Biological Technology
Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
...:45AM PST - Ofatumumab (HuMax-CD20),
a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with
CLL Refractory to Both Fludarabine and alemtuzumab
Fludarabine-Refractory Disease: Results from the Planned Interim Analysis
of An International Pivotal Trial.
Poster I-682 - Complement (C) ...
Genzyme Reports Strong Second-Quarter Growth
-- Genzyme continued to enroll patients in two ongoing Phase 3 trials
for the treatment of multiple sclerosis. Final, three-year
efficacy and safety data from the Phase 2 trial comparing alemtuzumab
Rebif(R) (interferon beta-1a) for the treatment of relapsing-remitting...
Genzyme Reports Strong First-Quarter Growth
...nical trials-particularly the phase 3 study of alemtuzumab
for multiple sclerosis. This estimate also re...st data package from Genzyme sponsored studies.
for multiple sclerosis
-- Final, three-year effi...d safety data from the Phase 2 trial comparing alemtuzumab
with Rebif (interferon beta-1a) for the treatment ...
Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
...atients who are refractory to both fludarabine and alemtuzumab
fludarabine refractory patients who are considered inappropriate candidates
due to bulky tumor in their lymph nodes. An interi...atients who are refractory to both fludarabine
and patients who are refractory to fludarabine who...